{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:20:38Z","timestamp":1792243238217,"version":"4.4.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pivotal clinical trials have assessed the efficacy and safety of fixed-dose upadacitinib 15\u2005mg (UPA15) and 30\u2005mg (UPA30) once daily in atopic dermatitis (AD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of dose escalation to UPA30 and dose reduction to UPA15 based on a clinical response [90% reduction in Eczema Area and Severity Index (EASI 90)] after 12 weeks of treatment in adults with moderate-to-severe AD enrolled in a randomized blinded treat-to-target multicentre phase IIIb\/IV study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 461 patients were randomized in a 1 : 1 ratio to receive oral doses of UPA15 (n = 229) or UPA30 (n = 232) once daily during the 12-week double-blinded period. At week 12, patients on UPA15 not achieving EASI 90 were dose escalated to UPA30 (UPA15\/30); patients achieving \u2265 EASI 90 continued on UPA15 (UPA15\/15). Patients on UPA30 not achieving EASI 90 at week 12 continued on UPA30 (UPA30\/30); patients achieving \u2265 EASI 90 received a reduced dose of UPA15 (UPA30\/15) for 12 additional weeks. The primary efficacy endpoint was EASI 90 achievement at week 24. Results were reported descriptively as observed. Safety outcomes were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At week 24, of patients who received dose escalation (UPA15\/30), 48.1% [n = 64\/133; 95% confidence interval (CI) 39.6\u201356.6] achieved EASI 90; of patients who received a dose reduction (UPA30\/15), 68.5% (n = 89\/130; 95% CI 60.5\u201376.4) maintained EASI 90. Of patients who continued on their initial dose, 29.3% (n = 24\/82; 95% CI 19.4\u201339.1) on UPA30\/30 achieved EASI 90 and 74.6% (n = 53\/71; 95% CI 64.5\u201384.8) on UPA15\/15 maintained EASI 90. At week 24, 32.5% (n = 27\/83; 95% CI 22.5\u201342.6) and 38.0% (n = 38\/100; 95% CI 28.5\u201347.5) of patients on UPA15\/30 and UPA30\/15, respectively, achieved a worst pruritus numerical rating scale score of 0 or 1 (WP-NRS 0\/1), and 20.7% (n = 17\/82; 95% CI 12.0\u201329.5) and 35.0% (n = 35\/100; 95% CI 25.7\u201344.3), respectively, achieved combined EASI 90 and WP-NRS 0\/1. At week 24, treatment emergent adverse events were reported in 43.1% (n = 31\/72; UPA15\/15), 54.2% (n = 78\/144; UPA15\/30), 61.5% (n = 56\/91; UPA30\/30) and 48.9% (n = 65\/133; UPA30\/15) of patients. No malignancies, adjudicated venous thromboembolic events or deaths were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment of moderate-to-severe AD with UPA15 or UPA30, with dose escalation or dose reduction based on achievement of the optimal treatment target of EASI 90 at week 12, demonstrated that both approaches support the achievement and maintenance of EASI 90 at week 24. Overall safety findings were consistent with the known UPA safety profile, with no new safety signals identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf236","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T07:50:50Z","timestamp":1750492250000},"page":"1101-1111","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of upadacitinib dose escalation and reduction in adults with moderate-to-severe atopic dermatitis: results of a randomized blinded treat-to-target multicentre phase IIIb\/IV study (Flex Up)"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0113","authenticated-orcid":false,"given":"Melinda","family":"Gooderham","sequence":"first","affiliation":[{"name":"Queen\u2019s University , Kingston, ON ,","place":["Canada"]},{"name":"SKiN Centre for Dermatology ,","place":["Canada"]},{"name":"Probity Medical Research ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio de Sto Ant\u00f3nio, University of Porto , Porto ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[{"name":"Fukuoka University Faculty of Medicine , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Rademaker","sequence":"additional","affiliation":[{"name":"Clinical Trials New Zealand, Waikato Hospital Campus , Hamilton ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal H","family":"Prajapati","sequence":"additional","affiliation":[{"name":"Probity Medical Research ,","place":["Canada"]},{"name":"Skin Health and Wellness Centre, Dermatology Research Institute , Calgary, AB ,","place":["Canada"]},{"name":"Dermatology Research Institute , Calgary, AB ,","place":["Canada"]},{"name":"Division of Dermatology, Department of Medicine and Sections of Community Pediatrics and Pediatric Rheumatology, University of Calgary , Calgary, AB ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Tsianakas","sequence":"additional","affiliation":[{"name":"Fachklinik Bad Bentheim , Bad Bentheim ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2971-0199","authenticated-orcid":false,"given":"Dedee F","family":"Murrell","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of New South Wales , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witold","family":"Owczarek","sequence":"additional","affiliation":[{"name":"Military Institute of Medicine , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Han","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Ju","family":"Lee","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gweneth","family":"Levy","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Moreira","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kave","family":"Shams","sequence":"additional","affiliation":[{"name":"Leeds Centre for Dermatology, Chapel Allerton Hospital , Leeds ,","place":["UK"]},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"2025111813171973100_ljaf236-B1","first-page":"83","article-title":"The challenge of managing atopic dermatitis in the United States","volume":"12","author":"Feldman","year":"2019","journal-title":"Am Health Drug Benefits"},{"key":"2025111813171973100_ljaf236-B2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/WOX.0b013e3181e2eb2e","article-title":"Dermatology for the allergist","volume":"3","author":"Kim","year":"2010","journal-title":"World Allergy Organ J"},{"key":"2025111813171973100_ljaf236-B3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"2025111813171973100_ljaf236-B4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000370220","article-title":"Atopic dermatitis: global epidemiology and risk factors","volume":"66","author":"Nutten","year":"2015","journal-title":"Ann Nutr Metab"},{"key":"2025111813171973100_ljaf236-B5","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jaad.2019.06.018","article-title":"Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis","volume":"81","author":"Egeberg","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025111813171973100_ljaf236-B6","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1111\/jdv.16329","article-title":"Therapeutic management of adults with atopic dermatitis: comparison with psoriasis and chronic urticaria","volume":"34","author":"Pascal","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025111813171973100_ljaf236-B7","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/jdv.20229","article-title":"Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis","volume":"38","author":"Silverberg","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025111813171973100_ljaf236-B8","author":"Rinvoq"},{"key":"2025111813171973100_ljaf236-B9","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"2025111813171973100_ljaf236-B10","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"2025111813171973100_ljaf236-B11","author":"European Medicines Agency. RINVOQ"},{"key":"2025111813171973100_ljaf236-B12","first-page":"44","article-title":"Diagnostic features of atopic dermatitis","volume":"60","author":"Hanifin","year":"1980","journal-title":"Acta Dermatovenereol"},{"key":"2025111813171973100_ljaf236-B13","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/jdv.18995","article-title":"Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient-reported symptom and quality of life measures: integrated analysis of three upadacitinib phase 3 trials","volume":"37","author":"Reich","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf236\/63546711\/ljaf236.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/6\/1101\/63546711\/ljaf236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/6\/1101\/63546711\/ljaf236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T18:17:24Z","timestamp":1763489844000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/6\/1101\/8171629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":13,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,23]]},"published-print":{"date-parts":[[2025,11,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf236","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,6,23]]}}}